ArticleSpringerPlus2014
The dependency of compound biological effectiveness factors on the type and the concentration of administered neutron capture agents in boron neutron capture therapy.
Article in SpringerPlus, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Development of Linear Interpolation System for SMK Model Parameters Evaluated from Cellular-Scale Simulation (LISMEC) and its application to BNCT dosimetry.Journal of radiation research · 2026Article
- The boron uptake via LAT1 and survival analysis after boron neutron capture therapy in canine hemangiosarcoma cell lines.Frontiers in veterinary science · 2026Article
- Neutron capture-enhanced proton beam therapy outside the irradiation field: in vitro experiments.BMC research notes · 2025Article
- Establishment of a practical methodology for evaluating equieffective dose of individual patients based on RT-PHITS.EJNMMI physics · 2025Article
- 'Cell knife' for cancer: the clinician's perspective.Frontiers in immunology · 2025Review
- Increased cell killing effect in neutron capture enhanced proton beam therapy.Scientific reports · 2024Article
- A national survey of medical staffs' required capability and workload for accelerator-based boron neutron capture therapy.Journal of radiation research · 2024Article
- Proposal of recommended experimental protocols for in vitro and in vivo evaluation methods of boron agents for neutron capture therapy.Journal of radiation research · 2023Article
- Next-Generation Boron Drugs and Rational Translational Studies Driving the Revival of BNCT.Cells · 2023Review
- The impact of TP53 status of tumor cells including the type and the concentration of administered 10B delivery agents on compound biological effectiveness in boron neutron capture therapy.Journal of radiation research · 2023Article
- Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient.Frontiers in oncology · 2023Article
- Scalp angiosarcoma treated with linear accelerator-based boron neutron capture therapy: A report of two patients.Clinical and translational radiation oncology · 2022Article
- Biodistribution ofBiomedicines · 2021Article
- Neutron flux evaluation model provided in the accelerator-based boron neutron capture therapy system employing a solid-state lithium target.Scientific reports · 2021Article
- An attempt to improve the therapeutic effect of boron neutron capture therapy using commonly employed 10B-carriers based on analytical studies on the correlation among quiescent tumor cell characteristics, tumor heterogeneity and cancer stemness.Journal of radiation research · 2020Article
- Folate receptor-targeted novel boron compound for boron neutron capture therapy on F98 glioma-bearing rats.Radiation and environmental biophysics · 2019Article
- Article
- Microdosimetric Modeling of Biological Effectiveness for Boron Neutron Capture Therapy Considering Intra- and Intercellular Heterogeneity inScientific reports · 2018Article
- Physics of epi-thermal boron neutron capture therapy (epi-thermal BNCT).Radiological physics and technology · 2017Review
- Evaluation of radioactivity in the bodies of mice induced by neutron exposure from an epi-thermal neutron source of an accelerator-based boron neutron capture therapy system.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine the effect of the type and the concentration of neutron capture agents on the values of compound biological effectiveness (CBE) in boron neutron capture therapy. METHODS AND MATERIALS: After the subcutaneous administration of a (10) B-carrier, boronophenylalanine- (10) B (BPA) or sodium mercaptododecaborate- (10) B (BSH), at 3 separate concentrations, the (10) B concentrations in tumors were measured by γ-ray spectrometry. SCC VII tumor-bearing C3H/He mice received 5-bromo-2'-deoxyuridine (BrdU) continuously to label all intratumor proliferating (P) cells, then treated with BPA or BSH. Immediately after reactor neutron beam irradiation, during which intratumor (10) B concentrations were kept at levels similar to each other, cells from some tumors were isolated and incubated with a cytokinesis blocker. The responses of BrdU-unlabeled quiescent (Q) and total (= P + Q) tumor cells were assessed based on the frequencies of micronucleation using immunofluorescence staining for BrdU.
resultsThe CBE values were higher in Q cells and in the use of BPA than total cells and BSH, respectively. In addition, the higher the administered concentrations were, the smaller the CBE values became, with a clearer tendency in the use of BPA than BSH. The values for neutron capture agents that deliver into solid tumors more dependently on uptake capacity of tumor cells became more changeable.
conclusionTumor characteristics, such as micro-environmental heterogeneity, stochastic genetic or epigenetic changes, or hierarchical organization of tumor cells, are thought to partially influence on the value of CBE, meaning that the CBE value itself may be one of the indices showing the degree of tumor heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.